Numerous disorders go untreated owing to a lack of a suitable drug delivery technology or
an appropriate therapeutic moiety, particularly when toxicities and side effects are a major …

Lung cancer is the most common type of cancer, with over 2.1 million cases diagnosed
annually worldwide. It has a high incidence and mortality rate, leading to extensive research …

Idiopathic pulmonary fibrosis (IPF) is a rare and severe disease with a median survival of~ 3
years. Nintedanib (NTD) has been shown to be useful in controlling interstitial lung disease …

Second-generation antipsychotics, quetiapine hemifumarate (QF), exhibited highly active
against negative and positive signs of psychosis. However, contemporary reports have …

Presently, non-invasive targeted drug delivery to the lungs represents a routinely
investigated approach to treat challenging disorders such as pulmonary fibrosis. Nintedanib …

Background Niosomes are versatile nanocarriers for therapeutic compounds, and optimizing
their structures via ionic surfactants can enhance their functionality considerably. Catanionic …

Niosomes are vesicular nanocarriers, biodegradable, relatively non-toxic, stable, and
inexpensive, that provide an alternative for lipid-solid carriers (eg, liposomes). Niosomes …

Nintedanib, a primary treatment for lung fibrosis, has gathered substantial attention due to its
multifaceted potential. A tyrosine kinase inhibitor, nintedanib, inhibits multiple signalling …

The key objective of this research work was to develop and evaluate dry powder for
inhalation containing lipid polymer hybrid nanoparticles (LPHNPs) loaded with Nintedanib …

Lung cancer is one of the most severe lethal malignancies, with approximately 1.6 million
deaths every year. Lung cancer can be broadly categorised into small and non-small-cell …